Key points are not available for this paper at this time.
Design
Review
Raises awareness of reperfusion injury risk in acute settings; leaves open targeted cardioprotection trials before practice change.
Reperfusion remains the sole proven means for limiting infarct size, but it may exact a pathologic price. Several observations support the belief that restoration of blood flow may promote the structural disruption of myocytes irreversibly injured by antecedent ischemia. If so, reperfusion would hasten cell death, in effect administering the coup de grace to myocardial tissue.
No takes yet. Share an insight, caveat, or question.
Jennings et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: